Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/26/2024 | $23.00 | Market Perform | Leerink Partners |
| 2/20/2024 | Hold → Reduce | HSBC Securities | |
| 1/3/2024 | $21.00 | Underweight | Barclays |
| 12/22/2023 | $27.00 | Hold | HSBC Securities |
| 10/23/2023 | $27.00 → $30.00 | Neutral → Overweight | JP Morgan |
| 7/3/2023 | $37.00 → $27.00 | Underweight | Morgan Stanley |
| 6/28/2023 | $46.00 → $34.00 | Buy → Hold | Deutsche Bank |
| 2/23/2023 | $45.00 | Buy | Loop Capital |
Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S. Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. This press release features multimedia. View the full release
Names Tracey Koller as Chief Merchandising Officer and Sharmila Sudhakar as Group Vice President and Head of Digital Commerce Walgreens, the leading independent retail pharmacy and healthcare provider, today announced two key leadership appointments: Tracey Koller, senior vice president and chief merchandising officer, and Sharmila Sudhakar, group vice president and head of Walgreens digital commerce. The company believes these new appointments will significantly contribute to its efforts with regard to the turnaround of the business as the company focuses on enhancing the front of store and omnichannel experience for its customers while driving in-store efficiencies. This press release
NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Super Micro Computer Inc. (NASDAQ:SMCI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 22, 2024. Super Micro Computer Inc. will replace Walgreens Boots Alliance Inc. (NASDAQ:WBA) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted Index. Walgreens Boots Alliance Inc. will also be removed from the Nasdaq-100 Ex-Tech Sector™ Index (NASDAQ:NDXX), the Nasdaq-100 ESG™ Index (NASDAQ:NDXESG), and the Nasdaq-100 Sustainable ESG Select™ Index (NASDAQ:NDXSES) on the same date. Super Micro Computer Inc
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs cut the price target for SunPower Corporation (NASDAQ:SPWR) from $2 to $0.5. Goldman Sachs analyst Brian Lee maintained a Sell rating. SunPower shares gained 5.4% to close at $0.7158 on Monday. See how other analysts view this stock. Piper Sandler increased the price target for Cathay General Bancorp (NASDAQ:CATY) from $32 to $36. Piper Sandler analyst Matthew Clark maintained an Underweight rating. Cathay General Bancorp shares gained 2.4% to close at $43.02 on Monday. See how other
Analysts' ratings for Walgreens Boots Alliance (NASDAQ:WBA) over the last quarter vary from bullish to bearish, as provided by 14 analysts. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 6 6 0 Last 30D 0 0 0 1 0 1M Ago 1 1 5 4 0 2M Ago 0 0 1 1 0 3M Ago 0 0 0 0 0 Analysts have recently evaluated Walgreens Boots Alliance and provided 12-month price targets. The average target is $13.86, accompanied by a high estimate of $22.00 and a low estimate of $7.00. A decline of 30.46% fro
Barclays analyst Steve Valiquette maintains Walgreens Boots Alliance (NASDAQ:WBA) with a Underweight and lowers the price target from $11 to $7.
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
BOWIE, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Inovalon, a leading provider of cloud-based software solutions empowering data-driven healthcare, welcomed industry trailblazers and visionary executives to the stage at Empower 2024, sparking meaningful conversations with leaders from every corner of healthcare. The annual summit, focused on the intersection of healthcare and technology, welcomed attendees in Washington, D.C., to showcase innovative strategies aimed at improving clinical, financial, and operational performance. Kicking off the summit, Keith Dunleavy, M.D., CEO and Founder of Inovalon, brought attendees through a technological innovation journey to highlight AI, machine learni
No-cost testing services are now available at stores across the country as part of expanded partnership with the CDC and HHS To help improve access to fast, reliable testing for veterans, Walgreens is now offering no-cost testing through a partnership with the Centers for Disease Control and Prevention (CDC).* Eligible veterans will be able to receive an easy combination test for COVID-19 and influenza at Walgreens locations across the country throughout this year's respiratory season, with results in 30 minutes or less.** No-cost COVID-19 and flu testing will also continue to be available at Walgreens for uninsured patients via the CDC program. This press release features multimedia. View
Walgreens encourages vaccination now ahead of the respiratory season and the holidays Walgreens has launched the 2024-2025 Walgreens Flu Index, an online, interactive tool that tracks weekly flu activity based on flu-related prescription data across the company's community pharmacy locations nationwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030359028/en/Young patient high-fives pharmacist after vaccination at Walgreens (Photo: Business Wire) For 11 years, the Walgreens Flu Index has provided an early and accurate view of disease trends. Historical data from the Walgreens Flu Index shows that southern states tend to s
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that its board of directors has declared a quarterly dividend of 25 cents per share, unchanged from the previous quarter. The dividend is payable on Dec. 12, 2024, to stockholders of record as of Nov. 18, 2024. Walgreens Boots Alliance and its predecessor company, Walgreen Co., have paid a dividend in 368 straight quarters (92 years). About Walgreens Boots Alliance Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities. A trusted, global innovator in retail pharmacy with approximately 1
Fourth Quarter In Line with Expectations; Announces Accretive Footprint Optimization Program Fourth quarter financial results Fourth quarter loss per share1 was $3.48 versus loss per share of $0.21 in the year-ago quarter. Loss per share in the current quarter includes a non-cash charge for valuation allowance on deferred tax assets primarily related to opioid liabilities recognized in prior periods, and non-cash impairment charges for CareCentrix goodwill and equity investment in China Adjusted earnings per share (Adjusted EPS2) was $0.39, down 40.8 percent on a constant currency basis driven by net reimbursement pressure, lapping the reversal of incentive accruals, and prior year sa
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) will release its fourth quarter and 2024 fiscal year-end results at 7 a.m. ET on Tuesday, October 15, 2024, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET. The conference call will be simulcast through the WBA investor relations website at: http://investor.walgreensbootsalliance.com. A replay will be archived on the website for 12 months after the call. About Walgreens Boots Alliance Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities. A trusted, global innovato
13F-HR - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
10-K - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
8-K - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00
HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce
Barclays initiated coverage of Walgreens Boots Alliance with a rating of Underweight and set a new price target of $21.00
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal